29 Nov, 2023
2 mins read

Novo Nordisk Intensifies Lobbying Efforts in Push for Medicare Coverage of Obesity Medications

Novo Nordisk, the manufacturer of the weight loss drug Wegovy as well as the diabetes medication Ozempic, spent lavishly on federal lobbying in the first half of 2023. The Danish pharmaceutical company is urging Congress to approve a bill that would eliminate Medicare coverage restrictions for weight management treatments. In the past three months, Novo […]

2 mins read

Wegovy: A Breakthrough in Weight Loss Medication Also Linked to Reduced Heart Disease Risk

The manufacturer of the diabetes and weight loss drug semaglutide (marketed under the brand names Wegovy and Ozempic) reported a 20% reduction in the risk of severe cardiovascular events, such as death, heart attack, and stroke. The drug manufacturer Novo Nordisk performed a five-year study of Wegovy, also known as semaglutide. The company gathered 17,604 […]